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(IANR) was held from October 2nd to 4th at the University of Rutgers, New Jersey,
USA, in which the most highlight was to report many frontier clinical trials. This
summary report tries to display mainly presenting achievements in this conference.
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The 11th Annual Conference of the International
Association of Neurorestoratology (IANR) was held
from October 2nd to 4th at the University of Rutgers,
New Jersey, the United States. Seventy speakers made
scientific reports at this conference. More than 200
experts from all over the world attended this meeting.
The contents are brilliant, which cover clinical trials
of spinal cord injury (SCI), brain injury, Parkinson’s
disease (PD), stroke, Alzheimer’s disease (AD),
amyotrophic lateral sclerosis (ALS) and Huntington’s
disease (HD). Therapeutic achievements by neurorestorative techniques or strategies including neuromodulation, brain stimulation, neural feedback, braincomputer interface (BCI), novel cells, nanomedicine,
peripheral nerve repair, revascularization technology
and new materials for bioengineering, etc. have been
reported. The Raisman Young Scholars Awards were
Corresponding author: Lin Chen, E-mail: chenlin_china@163.com

organized to contest and reward to the winners.
The second meeting of the Fourth Council Board of
the IANR discussed and decided that the 12th Annual
Conference would be held in Jordan and the 13th
Annual Conference would be held in Poland. The
Council Board also fully discussed how to make
the association’s official journal Journal of Neurorestoratology better and more popular.
The highlight of the conference was to actively
promote multi-country and international cooperation
to conduct multi-center randomized controlled clinical
trials. As we know, cell transplantation of multi-country
single-center was tested in different diseases or
damage, especially for complete SCI in latest 20 years.
Involving cells include olfactory ensheathing cells
(OECs), cord blood mononuclear cells, mesenchymal
stromal cells (MSCs) and Schwann cells (SCs), etc.
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Integrated neurorestoration (including cell therapy,
neuromodulation and rehabilitation etc.) treatment has
been able to restore patients with complete chronic
SCI some neurological functions; and partial patients
can even stand and walk again. However, in the
medical field, many doctors still maintain the view
that there is no neurorestorative effective treatment
for chronic SCI. So, the theme of this annual meeting
is “Neurorestoratology requires high-level evidencebased medicine”.
Below, this summary report shows parts of impressive
presentations of this conference to readers.

1

Clinical trials

1.1 Clinical trials for SCI
Wise Young from USA reported that Stemcyte has
proposed a Phase IIb clinical trial to assess the safety,
feasibility and efficacy of transplanting HLA-matched
umbilical cord blood mononuclear cells (UCBMNC)
into the spinal cord for 27 chronic complete SCI people,
with and without lithium carbonate followed by 6
months of intensive locomotor training. Code-named
US102D will randomize 27 patients to three treatments
groups: transplantation of a total of 6.4 million HLAmatched UCBMNC into spinal cord and a 6-week
course of oral placebo, transplantation of the cells
and a 6-week course of oral lithium carbonate. All the
patients will receive 6 months of intensive locomotor
training. On January 13th of 2017, Stemcyte submitted
an initial new drug / device (IND) application to the
Food and Drug Administration (FDA) for permission
to carry out this trial. The FDA requested additional
animal studies to assess the toxicity and migration of
UCBMNC transplanted into them spinal cord. After
a year of extensive animal studies, Stemcyte showed
that UCBMNC were well tolerated when transplanted
into immune-deficient rats, exhibited little or no toxicity
when transplanted into the spinal cord, did not result
in any tumors or loss of function in the animals. The
IND was resubmitted to the FDA and has essentially
been approved except for a clinical hold of the trial
until final validation of the hospital facility that will
be preparing the cells for transplantation. The trial
will be initiated soon.

Poon Wai Sang from Hong Kong of China
summarized the work of China Spinal Cord Injury
Network. More than 600 patients with chronic spinal
cord injuries into 8 clinical studies were recruited over
a 5-year period, gathering information on clinical
outcome natural history and efficacy information for
patients treated with lithium, methylprednesolone
and human umbilical cord blood mononuclear cells.
A 6-month course of intensive anti-gravity walking
exercise has been demonstrated to convey benefits to
sphincter function.
Hongyun Huang from China reported the design
that was to explore the safety and neurorestorative
effects of intramedullary decompression surgery for
acute complete spinal cord contusion injury.
Kyoung-Suok Cho from South Korea collected data
from 143 patients with cervical SCI. Based on the time
to surgical decompression, they grouped patients into
an ultra-early group (decompression within
8
hours of presentation) with 8 cases, an early group
(within 8–72 hours) with 75 cases, and a late group
(> 72 hours) with 60 cases. They compared the improvement in abbreviated injury scale (AIS) grade from
admission to discharge in each patient group. Results
showed that the patients who received surgery less than
8 hours after presentation had a significant improvement
in AIS grade from admission to discharge, as well as
a higher absolute AIS grade at discharge. There was
no difference in AIS grade for patients who received
surgery 8–72 hours after presentation and those who
received surgery > 72 hours after presentation. So,
surgical decompression within 8 hours in traumatic
SCI may optimize neurological recovery, especially in
patients with cervical SCI.
Moviglia Brandolino Maria Teresita from Argentina
reported intravascular implant with neural progenitor
cells and lymphocytes with intensive rehabilitation
program for patients with chronic and complete SCI,
who showed muscular functional recovery.
Keung Nyun Kim from South Korea reported that
open-label and nonrandomized controlled clinical
trial of human neural stem/progenitor cells (hNSPCs)
transplanted into the injured cord after traumatic
cervical SCI and showed modest neurological benefit
up to 1 year after transplants.
Lin Chen from China compared and analyzed the
effect of olfactory ensheathing cell intramedullary
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transplantation in multi-centers for complete chronic
SCI. The cell implantation into the spinal cord
parenchyma is effective for neurological functional
recovery and enough rehabilitation training is necessary
for the integration of motor recovery after cell transplantation, but improper procedures may lead to
ineffective results.
Hooshang Saberi from Iran performed a prospective,
double-blind, placebo-controlled and parallel randomized clinical trial through subcutaneous GranulocyteColony stimulating factor (G-CSF) administration
for incomplete sub-acute traumatic SCI. The results
showed that G-CSF administration made patients with
incomplete subacute traumatic SCI having significant
motor, sensory, and functional improvement.
Adeed Al-Zoubi from Jordan reported the results of
cell therapy for patients with SCI, who showed some
functional restoration.
1.2 Clinical trials for neurodegenerative diseases
Hongyun Huang and Gensheng Mao from China
demonstrated the mid-term results of a series cell
therapy of multicenter, randomized, double-blind and
placebo-controlled cell treatments for stroke, Parkinson’s
disease and Alzheimer’s disease, etc. Preliminary
results show partial involving trial’s patients getting
some benefits without side-effect, which is expected
to provide evidences of higher-level evidence-based
medicine, and ultimately makes cell therapy to be a
routine therapeutic technique for neurological diseases
and damage.
Anna Sarnowska reported preclinical and clinical
outcome of intraspinal transplantation of autologous
adipose-derived regenerative cells (ADRC) in six
patients with amyotrophic lateral sclerosis. The intraspinal ADRC transplantation at the Th10/11 level was
proved safe and well tolerated. In two patients, the
neurosurgery induced reduction of the muscle tone,
which resulted in improved walking capacity of a
one-month duration, objectively measured in one
case. There was also a reduction of progression rate
of the walking impairment within 3 months after the
transplantation in the same patient. From all applied
measures, Motor Unit Number Index (MUNIX) proved
to be the first and the most sensitive tool in identifying
fine changes at the muscle level. It was markedly more
sensitive than amyotrophic lateral sclerosis functional
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rating scale (ALSFRS-R) and Medical Research Council
(MRC) dyspnea scale. Moreover, in longitudinal
studies it was reduced not only in paretic but also in
presymptomatic muscles. The dynamometry was the
closest measurement to MUNIX, both on the upper and
lower limbs level. The Modified Ashworth Scale was
a sensitive tool in a potential patients’ stratification
according to the spasticity level. Among the analyzed
in cerebrospinal fluid (CSF) cytokines/chemokines
only six factors correlated with the therapeutic effect
of ADRC treatment. 24 hours after ADRC injection,
the level of all six cytokines was elevated, but after
3 months decrease of proinflammatory (TNFα, IFN-γ
and IL-1β) cytokines and increase of the growth factors
and anti-inflammatory/regressive agents like IL-6, bFGF
and MMP-9 were observed.
Shinn-Zong Lin conducted a phase I pilot trial to
study the safety and efficacy of intra-cerebral implantation of autologous adipose-derived stem cells (ADSC)
over peri-stroke area. Three patients were included.
Clinical evaluations included NIHSS, Fugl-Meyer score
and Barthel Index of Activities of Daily Living. These
patients showed remarkable amelioration of stroke
symptoms after ADSC transplantation and achieved
independent activity during their last follow-up (1, 3
and 6 months). There are no serious adverse effects
from implanted cells or surgical procedures.
Alok Sharma has shown that cell therapy is a safe
and an effective treatment option for some incurable
neurological disorders. The evidence of they have
published 9 clinical studies demonstrating the safety
and efficacy of intrathecal transplantation of autologous bone marrow mononuclear cells in various
incurable neurological disorders such as autism
spectrum disorder (ASD), cerebral palsy (CP), intellectual disability (ID), muscular dystrophy (MD), ALS,
thoracolumbar and cervical SCI, traumatic brain
injury (TBI) and brain stroke. In ASD, 92% of 32 cases
showed improvement in different aspects of Indian
Scale for Assessment of Autism (ISAA) along with
improved scores of Clinical Global Impressions Scale
(CGI) and Functional Independence Measure (FIM)
indicating cognitive and functional improvements. In
CP, 95% of 40 patients showed improved oromotor
activities, neck control, sitting, standing, walking
balance and speech with improved metabolism
recorded in the PET CT scan brain. In ID, outcome of 29

Journal of Neurorestoratology

4
patients of the intervention group was compared to
that of 29 patients from only rehabilitation group and
it was found that all patients in the intervention group
showed improvement while, there was no improvement in 20.69% patients from only rehabilitation group.
In MD, 86.67% of 150 MD patients showed improved
strength in trunk, upper and lower limbs and gait.
In ALS, it was found that the survival duration of the
treated population (n = 37) was 30.38 months more
than that of the control group (n = 20). In SCI, 91% of
110 thoracolumbar SCI patients and 74% of 56 cervical
SCI patients showed improvement in spasticity, sensation, trunk control, bladder management, standing
and sitting balance, ambulation and activities of daily
living (ADLs) along with FIM, American Spinal Cord
Injury Association (ASIA), and electromyogram/nerve
conduction velocity (EMG/NCV). In TBI, 93% of 14
TBI patients displayed improved balance, voluntary
control, muscle tone, oromotor activities, cognition,
coordination, speech, ambulation and ADLs after
intervention. In 24 patients of brain stroke, better
outcome was observed in patients with ischemic
stroke as compared to haemorrhagic stroke with
improvement in ambulation, hand function, standing
and walking balance.

2

Neuromodulation and brain machine
interface

Kenneth L. Shepard from USA developed a highchannel-count bioelectronic interface to sensory cortex.
The prototype device has 65 k electrodes for subdural
stimulation and recording. The entire device, including
the electrode array and all the associated electronics, is
integrated onto a single integrated circuit chip fabricated
in a complementary metal-oxide-semiconductor (CMOS)
process. This chip is thinned to less than 20 microns
while renders it flexible and conformal to the brain.
The chip is inserted with a small craniotomy which
allows the chip to be inserted in under the dura and
skull. A “relay station” outside the skull communicates
and powers the device wirelessly while acting as a
standard 802.11 wifi device.
Dennis J. McFarland from USA has shown that
over the past 30 years, brain-computer interface
research and development has grown into a very
active and exciting field. Its primary goal has been

to restore communication and control to those with
severe neuromuscular disabilities. At the same time,
it has become increasingly apparent over the past
decade that BCIs might also improve sensorimotor
rehabilitation for people with strokes or other
disorders, BCIs may be able to complement existing
therapies and enhance functional recovery. Several
different BCI-based rehabilitation strategies are under
study, the initial results are promising. Given the
extremely large numbers of people who might benefit,
neurorehabilitation may eventually prove to be the
most important application of BCI technology.
Yong Hu from Hong Kong of China reported that
brain stimulation, neural feedback and brain machine
interface with rehabilitative interventions can improve
neurological function for various neurological diseases
and disorders, such as stroke or brain injury and
SCI. The main mechanism is the brain plasticity or
neuroplasticity refers to the neural functional and
structural changes in response to neuromodulation
and training.
Winfried Mayr from Austria introduced that
integration of externally controlled afferents and
residual motor control of impaired central neural
system (CNS) opened new effective possibilities in
restoring movement and artificial afferent input to
spinal interneuron networks provided important complementary options to influence movement and sensory
functions.

3

Neurorestorative pharmacotherapy

Non-invasive techniques based on colloidal carriers
could represent a huge potential, since nanocarriers
(polymeric nanoparticles, nanoliposomes, solid-lipid
nanoparticles (SLN), nanostructured lipid carriers
(NLC), micelles, nanogels and dendrimers could
protect the drugs (or gene material) and deliver them
to CNS. Giovanni Tosi from Italy introduced the main
advantages of the use of nanomedicine-based approach
for innovation in crossing the most “defensive” barrier,
with relevance to neurodegenerative diseases.

4

Tissue engineering and bioengineering

Wuh-Liang Hwu used a gene therapy for aromatic
L-amino acid decarboxylase (AADC) deficiency results
Journal of Neurorestoratology
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in de novo dopamine production and supported durable
improvement in major motor milestones. They have
treated 25 patients using a single administration of
GT-AADC delivered bilaterally to the putamen by
stereotactic infusions during a single, operative
session in single-arm, open label clinical studies in
their hospital. Patients received a total dose of either
1.8 × 1011 μg total of GT-AADC (n = 21) or 2.4 × 1011 μg
total of GT-AADC (n = 4). Of the 25 children, 3 are
now more than 7-year, 4 are more than 6-year, and 9
are more than 2-year post-gene therapy. Clinical results
of the first 18 patients were compared to natural
history cohort. At baseline (21 months to 8.5 years
old), no child had developed full head control, sitting
unassisted or standing capability, consistent with the
published natural history cohort of severe AADC
patients. After gene therapy, all patients exhibited
increase scores in motor scales and gained new motor
function. Objective evidence for de novo dopamine
production was obtained from CSF homovanillic acid
(HVA) levels and 6-[1⁸F]-fluoro-l-DOPA (FDOPA)
positron emission tomography (PET). CSF HVA levels
increased significantly one year after gene therapy.
FDOPA uptaken in bilateral putamens also increased
one year after gene therapy, and was stable over five
years after gene therapy.
Damien P. Kuffler showed that the application of
platelet-rich plasma (PRP) to the ends of nerve stumps
reduces / eliminates chronic neuropathic pain. Then,
they have finished a clinical study in which following
extremity amputations, the major exposed nerve
stumps were secured within a closed ended collagen
tube filled with PRP to prevent the development of
phantom limb pain (PLP).

5

Neurorestorative surgery

Justin Brown from USA introduced the procedures
applied to the central or peripheral nervous system
that correct deficits by augmenting neural control,
restoring neural connectivity and redistributing intact
residual functions.
Hongyan Han from China reported that 528
patients with Moyamoya disease got novel combined
bypass surgery, that is, superficial temporal artery to
middle cerebral artery (STA-MCA) anastomosis and
encephaloduro-myo-arterio-pericranio-synangiosis
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(EDMAPS). Those revascularization procedures
restored some neurological functions by improving
cerebral hemodynamics in both the MCA and anterior
cerebral artery (ACA) territories.

6 Therapeutic policy of Neurorestoratology
Russell Andrews from USA presented related issues of
Neurorestoratology at the policy level: disaster response
centers. To improve morbidity / mortality in disasters
both natural and man-made (terrorism, building
collapse and transportation accidents), disaster response
(DR) must be on-site within 24 hours, not the days to
weeks of current DR (e.g., UN, WHO, Red Cross).
Ziad M. Al Zoubi from Jordan pointed out that
cellular therapy has some obstacles to the growth and
development of this new form of treatment. Based on
several documents and researches, it is proposed to
recommend to regulatory bodies and medical associations an alternate way of looking at regulations for cell
therapy so that simultaneous to ensuring that only
safe and effective treatment are offered to patients,
greater availability of these new treatment options is
also encouraging. These recommendations are greater
permissiveness for use of cell therapy in incurable
conditions, identifying legitimate cell therapy services,
promoting medical innovation, respecting the rights
of patients to choose treatments, recognizing the
valid compassionate use of unapproved therapies,
recognizing the significance of small functional gains,
giving importance to practice based evidence and
existing published literature and having differing
regulations for the different types of cell therapies.
At the same time, he suggested to widen the era of
researches during the next conference to include the
trials on the musculoskeletal organs which is primarily
related to Neurorestoratology, during the next conference
in Amman / Jordan there will be sessions on the trials
of cell therapy in bone, joints and muscles.
Gustavo A. Moviglia proposed the clinical trial of
cellular therapy for stroke during its subacute phase.
Based on the facts and what they have observed during
their pre-clinical and clinical experience working on
SCI, he suggested to perform a Proof of Concept
Clinical trial, if days 6 and 8, will be optimal for the
treatment of stroke patients with endothelial cellscentral nervous system (EC-CNS) and neural progenitor
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cells (NPC), respectively. It is done with the goal to
stabilize, probably improve, the brain lesion and the
clinical outcome of these patients.
Shiqing Feng from China analyzed the problems of
clinical cell transplantation in the treatment of spinal
cord injury and suggested to better understand the
merits, demerits and precise function of different
cells for SCI.
Sang Ryong Jeon from South Korea proposed that
the future strategy should focus on the ways to enhance
the effects of cell therapy such as materials to be
combined with cells, gene modification for secreting
trophic factors or cytokines.
Siwei You from China suggested to make combinational efforts of basic and clinical vision scientists
for clinical applications of these achievements, then
effectively enhanced the restoration of injured optic
nerve.

7

Basic and preclinical research of
Neurorestoratology

Jason B. Carmel from USA targeted the spinal cord
through the strong interaction of the corticospinal
tract (CST) and large diameter afferent fibers, which
mediated the senses of joint position and muscle
tension. They hypothesized that repetitive pairing
motor cortex and sensory spinal cord would strengthen
sensorimotor integration in the cervical spinal cord of
rats. Indeed, sub-threshold spinal cord stimulation
strongly augments motor cortex evoked muscle responses when they are timed to arrive synchronously
in the spinal cord. When pairing is performed
repeatedly, there is more than a doubling of muscle
responses that lasts for up to 2 hours after just
5 minutes of pairing. They also tested the necessity
and sufficiency of the CST and large-diameter afferents
by selective viral inactivation. Both CST and large
diameter afferents were necessary for the paired
stimulation effects; inactivation completely abrogated
the paired stimulation effects. Selective stimulation
of the CST at the pyramid or dorsal roots was also
enough for the paired stimulation effect. Finally, they
examined the effects of paired stimulation on motor
outcomes after spinal cord injury. Adult rats were
subjected to a moderate C4 contusion injury followed
ten days later by ten days of paired stimulation.

Control rats had sham stimulation and all rats were
tested by blinded evaluators on two tests of skilled
motor function. Rats with electrical stimulation had
improved function on both a skilled walking task
and a food manipulation task. Since motor cortex and
cervical spinal cord are safely stimulated in people, this
approach could be translated quickly to clinical trials.
Fabin Han from China reported that rats with
transplanted inducing pluripotent stem cells to neural
stem cells (iPSC-NSCs) showed progressive improvements in motor behaviors compared to controls from
weeks 4 to 16 post-grafting. These results demonstrated
the efficacy and usefulness of the growth cocktail
in combination with iPSC-NSCs transplantation in
6-OHDA lesioned rats, which provided a promising
cell-based treatment strategy for the PD patients.
Ki Bum Lee from USA focused on the synthesis and
utilization of multifunctional nanoparticles as drug and
gene delivery vehicles to manipulate the expression of
key genes in stem cells and somatic cells for cellular
reprogramming. One of the approaches includes
developing an artificial, nanoparticle-based transcription
factor (termed NanoScript) to provide an innovate
approach to differentiate stem cells in an effective,
selective and non-viral manner. Another approach
includes combinatorial nanoarrays of graphenenanoparticle hybrid structures using nanoparticles and
chemically derived graphene, graphene-nanofiber
hybrid scaffolds and biodegradable hybrid nanoscaffolds were developed and utilized to deliver genetic
materials into stem cells for controlling their neuraldifferentiation pathways and neuronal behaviors.
Mari Dezawa from Japan described one endogenous
pluripotent multilineage-differentiating stress enduring
(Muse) cells, which may revolutionize medical care.
Muse cells are naturally existing unique endogenous
stem cells that are non-tumorigenic and are pluripotentlike. They express pluripotent markers, can generate
cells representative of all three germ layers from a
single cell and are able to self-renew. Recently, Muse
cells are shown to circulate in peripheral blood in
healthy donors, and the number increases in stroke
and acute myocardial infarction (AMI) patients in an
acute phase, suggesting that endogenous Muse cells
are mobilized into peripheral blood to repair tissues
while their number is not enough to recover, and that
supply of exogenous Muse cells is expected to deliver
Journal of Neurorestoratology
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statistically meaningful functional recovery. The phase
I clinical study for AMI and stroke is conducted based
on intravenous drip of donor-derived Muse cells.
Inbo Han from South Korea reported that injecting
iron oxide nanoparticle-incorporated exosome-mimetic
nanovesicles from mesenchymal stromal cells (NV-IONP)
could enhance the blood vessel formation, attenuate the
inflammation and apoptosis in the injured spinal cord,
and consequently improve the spinal cord functions.
Francesca Citthetti from Canada reported her
preliminary data, which confirmed the contribution
of the circulatory system to mutant huntingtin (mHtt)
dissemination. This means that mHtt can cross the
blood-brain-barrier and spread within the brain of
wild-typ (WT) mice. Also, this technique will further
determine if rejuvenating blood factors from the healthy
WT parabiont can alleviate HD-related pathology/
phenotype in transgenic animals.
Na Liu from China reported that adipose-derived
stromal cells overexpressing CX3CR1 demonstrated
an increased migration ability in both in vitro and in
vivo models, and improved therapeutic outcomes in
the intracerebral hemorrhage animal model.
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therapies and push them to translation into clinic.
From clinical viewpoints, it is very urgent to do multicenter randomized double-blind controlled clinical trial
for promising and potential neurorestorative therapies,
in order to make them to be routine therapeutic
methods for patients with neurological diseases and
damage including chronic complete SCI.
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8 Short summary
Both scientists and physicians in the world are trying
their best to explore more effective neurorestorative
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